Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company focused on developing small-molecule kinase inhibitors for neurodegenerative and infectious diseases. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on therapies that target disease mechanisms involving Abelson tyrosine kinase (c-Abl). Its lead development programs are directed toward Parkinson’s disease and pulmonary arterial hypertension (PAH), with earlier research also evaluating applications in infectious diseases.
The company’s core product candidate, IkT-148009, is an oral c-Abl inhibitor designed to penetrate the central nervous system and modulate neuroinflammation and neurodegeneration. Inhibikase was founded in 2008 and became publicly traded in 2020 through an initial public offering. Since inception, the company has evolved from early-stage discovery into clinical development, advancing its lead asset through Phase 2 clinical evaluation while remaining pre-revenue and dependent on external financing.
Business Operations
Inhibikase operates as a single-segment clinical-stage biotechnology company, generating no commercial product revenue to date. Its operations are primarily focused on research and development, including preclinical studies, clinical trials, regulatory strategy, and intellectual property management. The company’s expenses are largely driven by clinical trial costs, manufacturing of clinical-grade drug substance, and general corporate overhead.
The company conducts its development activities through a combination of internal scientific leadership and outsourced relationships with contract research organizations (CROs) and contract manufacturing organizations (CMOs). Inhibikase does not currently report any material subsidiaries, joint ventures, or revenue-generating partnerships; data inconclusive based on available public sources regarding any controlled operating subsidiaries beyond the parent entity.
Strategic Position & Investments
Strategically, Inhibikase is focused on advancing IkT-148009 through mid-stage clinical development, with the goal of addressing diseases that have significant unmet medical need and limited disease-modifying treatment options. The company’s growth strategy centers on achieving clinical proof-of-concept in Parkinson’s disease and PAH, which management believes could support future partnering, licensing, or capital-raising opportunities.
The company has not disclosed any completed acquisitions of other biotechnology companies or marketed products. Its primary investment is internal—concentrated on its proprietary c-Abl inhibition platform and related intellectual property portfolio. While management has indicated interest in expanding the platform to additional indications, publicly available filings show no material equity investments or portfolio company holdings as of the most recent reporting periods.
Geographic Footprint
Inhibikase is headquartered in the United States, with corporate offices located in New York, New York. The company’s operational footprint is limited, reflecting its clinical-stage status, and it does not maintain commercial infrastructure or manufacturing facilities of its own.
Clinical and research activities extend internationally through third-party vendors, including clinical trial sites and service providers in North America and Europe. Despite this international operational reach, Inhibikase’s strategic control, decision-making, and regulatory interactions remain primarily centered in the United States.
Leadership & Governance
Inhibikase is led by a management team with experience in drug development, neuroscience, and public biotechnology company operations. The leadership team emphasizes a science-driven strategy focused on rigorous clinical validation and capital efficiency. Governance is overseen by a board of directors with backgrounds in biotechnology, finance, and pharmaceutical development.
Key executives include:
- Milton H. Werner, Ph.D. – President & Chief Executive Officer
- Lawrence C. Lee, M.D. – Chief Medical Officer
- Christopher S. Pan, M.D. – Chief Operating Officer
- William A. Feuerstein – Chief Financial Officer
- Lindsay A. Rosenwald, M.D. – Founder & Chairman of the Board
The leadership’s stated strategic vision, as reflected in public filings and investor communications, is to advance differentiated kinase inhibitors into clinically meaningful therapies for patients with serious, underserved diseases.